KR102247795B1 - 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 - Google Patents

급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 Download PDF

Info

Publication number
KR102247795B1
KR102247795B1 KR1020180131294A KR20180131294A KR102247795B1 KR 102247795 B1 KR102247795 B1 KR 102247795B1 KR 1020180131294 A KR1020180131294 A KR 1020180131294A KR 20180131294 A KR20180131294 A KR 20180131294A KR 102247795 B1 KR102247795 B1 KR 102247795B1
Authority
KR
South Korea
Prior art keywords
compound
imino
ethoxy
biindolinylidine
flt3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180131294A
Other languages
English (en)
Korean (ko)
Other versions
KR20190049584A (ko
KR102247795B9 (ko
Inventor
김용철
유현
정평화
Original Assignee
주식회사 펠레메드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 펠레메드 filed Critical 주식회사 펠레메드
Publication of KR20190049584A publication Critical patent/KR20190049584A/ko
Application granted granted Critical
Publication of KR102247795B1 publication Critical patent/KR102247795B1/ko
Publication of KR102247795B9 publication Critical patent/KR102247795B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020180131294A 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 Active KR102247795B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170144142 2017-10-31
KR20170144142 2017-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210052728A Division KR20210047850A (ko) 2021-04-23 2021-04-23 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Publications (3)

Publication Number Publication Date
KR20190049584A KR20190049584A (ko) 2019-05-09
KR102247795B1 true KR102247795B1 (ko) 2021-05-04
KR102247795B9 KR102247795B9 (ko) 2023-04-12

Family

ID=66333236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180131294A Active KR102247795B1 (ko) 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Country Status (12)

Country Link
US (1) US11370779B2 (https=)
EP (1) EP3705474A4 (https=)
JP (1) JP7005779B2 (https=)
KR (1) KR102247795B1 (https=)
CN (1) CN111542513A (https=)
AU (1) AU2018358582B2 (https=)
BR (1) BR112020008499A2 (https=)
CA (1) CA3080900C (https=)
MX (1) MX2020004374A (https=)
PH (1) PH12020550491A1 (https=)
RU (1) RU2763346C2 (https=)
WO (1) WO2019088677A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433834B2 (en) 2019-04-26 2025-10-07 Conopco, Inc. Hair conditioning composition
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
CN114521142B (zh) * 2019-11-04 2024-07-02 Ck雷容股份有限公司 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
KR102296440B1 (ko) * 2019-12-06 2021-09-02 주식회사 펠레메드 신규한 인디루빈 유도체 및 이의 용도
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR102278176B1 (ko) 2020-02-20 2021-07-16 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR20210106155A (ko) 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102325607B1 (ko) 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
KR102744517B1 (ko) * 2022-02-14 2024-12-19 주식회사 펠레메드 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도
WO2024181799A1 (ko) * 2023-02-28 2024-09-06 주식회사 씨케이리제온 신규한 인돌린 유도체 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007099402A2 (en) 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications
WO2010013168A1 (en) 2008-08-01 2010-02-04 Centre National De La Recherche Scientifique (Cnrs) 3',6-substituted indirubins and their biological applications
US20140275168A1 (en) 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010735A2 (en) * 1999-04-12 2002-12-31 Gerhard Eisenbrand Indigoid bisindole derivatives
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR100588803B1 (ko) 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
KR101180030B1 (ko) * 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
US20150087687A1 (en) * 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CA2902914A1 (en) * 2013-03-14 2014-09-25 City Of Hope 5-bromo-indirubins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007099402A2 (en) 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications
WO2010013168A1 (en) 2008-08-01 2010-02-04 Centre National De La Recherche Scientifique (Cnrs) 3',6-substituted indirubins and their biological applications
US20140275168A1 (en) 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Also Published As

Publication number Publication date
US20200270229A1 (en) 2020-08-27
CA3080900A1 (en) 2019-05-09
RU2020115581A (ru) 2021-12-02
RU2020115581A3 (https=) 2021-12-02
JP7005779B2 (ja) 2022-02-10
WO2019088677A1 (ko) 2019-05-09
JP2021501208A (ja) 2021-01-14
RU2763346C2 (ru) 2021-12-28
CA3080900C (en) 2022-10-25
AU2018358582B2 (en) 2021-06-10
AU2018358582A1 (en) 2020-05-07
KR20190049584A (ko) 2019-05-09
CN111542513A (zh) 2020-08-14
MX2020004374A (es) 2020-11-11
PH12020550491A1 (en) 2021-01-11
BR112020008499A2 (pt) 2020-10-20
EP3705474A1 (en) 2020-09-09
KR102247795B9 (ko) 2023-04-12
EP3705474A4 (en) 2021-06-09
US11370779B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
KR102247795B1 (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
EP2958911B1 (en) Quinazolines as kinase inhibitors
CA2863673A1 (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
HUE027534T2 (en) Notch pathway inhibitory compound
WO2014086102A1 (zh) 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
JP2025503139A (ja) 固形腫瘍の治療のためのユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤
AU2019218186A1 (en) Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
US20260078121A1 (en) Inhibitors of enl/af9 yeats and flt3
WO2019029629A1 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS
KR20210047850A (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
CN104876914B (zh) 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
AU757611B2 (en) Optically active pyrrolopyridazine compounds
EP3750893B1 (en) Dioxazoline compound, preparation method therefor, and uses thereof
KR101083421B1 (ko) 신규 피라졸로이미다졸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 비정상 세포 성장 질환의 예방 및 치료용 약학적 조성물
CN106467540A (zh) 蝶啶酮衍生物作为flt3抑制剂的应用
KR20140095325A (ko) Lyn 키나제에 대하여 저해 활성을 갖는 아미노퀴나졸린 유도체
CN106146525A (zh) 三并环类间变性淋巴瘤激酶抑制剂
CA3090829A1 (en) Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
KR100714370B1 (ko) 항종양 활성을 갖는〔1,2,4〕―트리아졸로〔4,3―ｃ〕퀴나졸린 유도체
KR101995533B1 (ko) [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
CN120035595A (zh) 噻唑并[5,4-d]嘧啶化合物、包含其的组合物及其用途
KR20210060461A (ko) 피롤 치환된 인돌리논계 유도체 또는 이의 약학적으로 허용 가능한 염, 및 이의 제조 방법 및 이의 용도

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20230412

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1022477950000

Gazette reference publication date: 20210504

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000